|
US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
|
US3935230A
(en)
|
1972-10-24 |
1976-01-27 |
E. R. Squibb & Sons, Inc. |
α, α, α, α', α', α'-Hexafluorodi-m-tolylamine derivatives
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
DE4134467A1
(de)
|
1991-10-18 |
1993-04-22 |
Thomae Gmbh Dr K |
Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
US5441952A
(en)
|
1993-04-05 |
1995-08-15 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
EA199700209A1
(ru)
|
1995-04-04 |
1998-04-30 |
Глаксо Груп Лимитед |
ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА
|
|
DK0821671T3
(da)
|
1995-04-20 |
2001-04-23 |
Pfizer |
Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
DE69624081T2
(de)
|
1995-12-20 |
2003-06-12 |
Agouron Pharmaceuticals, Inc. |
Matrix-metalloprotease Inhibitoren
|
|
WO1997023508A1
(en)
|
1995-12-22 |
1997-07-03 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
|
US6291455B1
(en)
|
1996-03-05 |
2001-09-18 |
Zeneca Limited |
4-anilinoquinazoline derivatives
|
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
|
ES2191187T3
(es)
|
1996-07-13 |
2003-09-01 |
Glaxo Group Ltd |
Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
ID19609A
(id)
|
1996-07-13 |
1998-07-23 |
Glaxo Group Ltd |
Senyawa-senyawa heterosiklik
|
|
EP0923585B1
(en)
|
1996-07-18 |
2002-05-08 |
Pfizer Inc. |
Phosphinate based inhibitors of matrix metalloproteases
|
|
WO1998007697A1
(en)
|
1996-08-23 |
1998-02-26 |
Pfizer Inc. |
Arylsulfonylamino hydroxamic acid derivatives
|
|
NZ330571A
(en)
|
1996-10-01 |
1999-10-28 |
Kyowa Hakko Kogyo Kk |
Nitrogenous heterocyclic compounds that may contain sulphur or oxygen
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
WO1998030566A1
(en)
|
1997-01-06 |
1998-07-16 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
|
EP0977733B1
(en)
|
1997-02-03 |
2003-09-03 |
Pfizer Products Inc. |
Arylsulfonylamino hydroxamic acid derivatives
|
|
JP2000507975A
(ja)
|
1997-02-07 |
2000-06-27 |
ファイザー・インク |
Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
|
|
EA002546B1
(ru)
|
1997-02-11 |
2002-06-27 |
Пфайзер Инк. |
Производные арилсульфонилгидроксамовой кислоты
|
|
EP0984930B1
(en)
|
1997-05-07 |
2005-04-06 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
CA2291709A1
(en)
|
1997-05-30 |
1998-12-03 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
AU730248B2
(en)
|
1997-08-08 |
2001-03-01 |
Pfizer Products Inc. |
Aryloxyarylsulfonylamino hydroxamic acid derivatives
|
|
WO1999010349A1
(en)
|
1997-08-22 |
1999-03-04 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
|
WO1999016755A1
(en)
|
1997-09-26 |
1999-04-08 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
CA2309690A1
(en)
|
1997-11-11 |
1999-05-20 |
Pfizer Products Inc. |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
PT952148E
(pt)
|
1998-04-10 |
2004-09-30 |
Pfizer Prod Inc |
Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamico
|
|
EA005032B1
(ru)
|
1998-05-29 |
2004-10-28 |
Сьюджен, Инк. |
Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
|
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
|
DK1004578T3
(da)
|
1998-11-05 |
2004-06-28 |
Pfizer Prod Inc |
5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
|
|
AU776788C
(en)
|
1998-12-16 |
2005-10-27 |
Warner-Lambert Company |
Treatment of arthritis with MEK inhibitors
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
SK11002001A3
(sk)
|
1999-02-11 |
2002-05-09 |
Pfizer Products Inc. |
Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky
|
|
IL129299A0
(en)
|
1999-03-31 |
2000-02-17 |
Mor Research Applic Ltd |
Monoclonal antibodies antigens and diagnosis of malignant diseases
|
|
AU784634B2
(en)
|
1999-11-30 |
2006-05-18 |
Mayo Foundation For Medical Education And Research |
B7-H1, a novel immunoregulatory molecule
|
|
SI1255752T1
(sl)
|
2000-02-15 |
2007-12-31 |
Pharmacia & Upjohn Co Llc |
S pirolom substituirani zaviralci 2-indolinon protein kinaza
|
|
EP1257546A1
(en)
|
2000-02-17 |
2002-11-20 |
Amgen Inc. |
Kinase inhibitors
|
|
DZ3401A1
(fr)
|
2000-07-19 |
2002-01-24 |
Warner Lambert Co |
Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
|
|
AU8544901A
(en)
|
2000-08-18 |
2002-03-04 |
Cor Therapeutics Inc |
Quinazoline derivatives as kinase inhibitors
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
AU2003224672B2
(en)
|
2002-03-08 |
2010-02-04 |
Eisai R&D Management Co., Ltd. |
Macrocyclic compounds useful as pharmaceuticals
|
|
SG2013013339A
(en)
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
WO2003095448A1
(en)
|
2002-05-06 |
2003-11-20 |
Bayer Pharmaceuticals Corporation |
Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
AU2003272548A1
(en)
|
2002-09-16 |
2004-04-30 |
Plexxikon, Inc. |
Crystal structure of pim-1 kinase
|
|
US20040115226A1
(en)
|
2002-12-12 |
2004-06-17 |
Wenji Li |
Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
|
|
WO2004058769A2
(en)
|
2002-12-18 |
2004-07-15 |
Vertex Pharmaceuticals Incorporated |
Triazolopyridazines as protein kinases inhibitors
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
JP2006151810A
(ja)
|
2002-12-26 |
2006-06-15 |
Daiichi Asubio Pharma Co Ltd |
ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤
|
|
CA2515190A1
(en)
|
2003-02-14 |
2004-08-26 |
Pfizer Products Inc. |
Triazolo-pyridines as anti-inflammatory compounds
|
|
ES2325440T3
(es)
|
2003-02-20 |
2009-09-04 |
Smithkline Beecham Corporation |
Compuestos de pirimidina.
|
|
MXPA06003054A
(es)
|
2003-09-18 |
2006-05-31 |
Novartis Ag |
2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
|
|
AU2004282179B2
(en)
|
2003-10-14 |
2011-05-19 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Protein kinase inhibitors
|
|
PL1778686T3
(pl)
|
2004-08-12 |
2009-04-30 |
Pfizer |
Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
|
|
TW200633990A
(en)
|
2004-11-18 |
2006-10-01 |
Takeda Pharmaceuticals Co |
Amide compound
|
|
US7723340B2
(en)
|
2005-01-13 |
2010-05-25 |
Signal Pharmaceuticals, Llc |
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
|
|
CA2499782A1
(en)
*
|
2005-03-07 |
2006-09-07 |
Queen's University At Kingston |
Sol gel functionalized silicate catalyst and scavenger
|
|
US20090029982A1
(en)
|
2005-04-28 |
2009-01-29 |
Supergen, Inc. |
Protein kinase inhibitors
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
MX2008002114A
(es)
|
2005-07-21 |
2008-04-17 |
Ardea Biosciences Inc |
Inhibidores de n-(arilamino)-sulfonamida de mek.
|
|
JP2009502734A
(ja)
|
2005-07-29 |
2009-01-29 |
アステラス製薬株式会社 |
Ｌｃｋ阻害剤としての縮合複素環
|
|
WO2007020888A1
(ja)
|
2005-08-12 |
2007-02-22 |
Takeda Pharmaceutical Company Limited |
脳・神経細胞保護剤および睡眠障害治療薬
|
|
WO2007025090A2
(en)
|
2005-08-25 |
2007-03-01 |
Kalypsys, Inc. |
Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
|
|
US7750000B2
(en)
|
2005-09-02 |
2010-07-06 |
Bayer Schering Pharma Ag |
Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
|
|
DE102005042742A1
(de)
|
2005-09-02 |
2007-03-08 |
Schering Ag |
Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
|
CN101321760A
(zh)
|
2005-10-06 |
2008-12-10 |
先灵公司 |
作为蛋白激酶抑制剂的吡唑并嘧啶
|
|
KR20080098490A
(ko)
|
2006-01-13 |
2008-11-10 |
파마시클릭스, 인코포레이티드 |
티로신 키나제 억제제 및 이의 용도
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
WO2007091152A1
(en)
|
2006-02-09 |
2007-08-16 |
Pfizer Limited |
Triazolopyridine compounds
|
|
BRPI0712332A2
(pt)
|
2006-06-09 |
2012-12-18 |
Icos Corp |
composto e derivados farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, método de antagonização de um receptor dp-2, e, uso de um composto
|
|
DE102006029447A1
(de)
|
2006-06-21 |
2007-12-27 |
Bayer Schering Pharma Ag |
Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
|
|
EP1873157A1
(en)
|
2006-06-21 |
2008-01-02 |
Bayer Schering Pharma Aktiengesellschaft |
Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
|
|
EP1900739A1
(en)
|
2006-08-30 |
2008-03-19 |
Cellzome Ag |
Diazolodiazine derivatives as kinase inhibitors
|
|
CA2663091A1
(en)
|
2006-09-07 |
2008-03-13 |
Biogen Idec Ma Inc. |
Modulators of interleukin-1 receptor-associated kinase
|
|
BRPI0622054B8
(pt)
|
2006-09-22 |
2021-05-25 |
Oxford Amherst Llc |
composto e composição farmacêutica
|
|
WO2008037477A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as p13k lipid kinase inhibitors
|
|
CN101522682A
(zh)
|
2006-10-30 |
2009-09-02 |
诺瓦提斯公司 |
作为抗炎剂的杂环化合物
|
|
WO2008055233A1
(en)
|
2006-10-31 |
2008-05-08 |
Supergen, Inc. |
Protein kinase inhibitors
|
|
CA2668286C
(en)
|
2006-11-03 |
2014-09-16 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
BRPI0718029A2
(pt)
|
2006-11-06 |
2013-11-26 |
Supergen Inc |
Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
|
|
US20120058997A1
(en)
|
2006-11-06 |
2012-03-08 |
Supergen, Inc. |
Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
|
|
WO2008082839A2
(en)
|
2006-12-29 |
2008-07-10 |
Abbott Laboratories |
Pim kinase inhibitors as cancer chemotherapeutics
|
|
US8846704B2
(en)
|
2007-01-31 |
2014-09-30 |
YM Biosciences Austraila Pty Ltd |
Thiopyrimidine-based compounds and uses thereof
|
|
MX2009009117A
(es)
|
2007-03-01 |
2009-09-03 |
Supergen Inc |
Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
|
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
|
WO2008118823A2
(en)
|
2007-03-26 |
2008-10-02 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
IL295053A
(en)
|
2007-03-28 |
2022-09-01 |
Pharmacyclics Llc |
Broton tyrosine kinase inhibitors
|
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
EP2139869A2
(en)
|
2007-04-13 |
2010-01-06 |
SuperGen, Inc. |
Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
WO2009017954A1
(en)
|
2007-08-01 |
2009-02-05 |
Phenomix Corporation |
Inhibitors of jak2 kinase
|
|
AU2008298948B2
(en)
|
2007-09-12 |
2014-09-04 |
F. Hoffmann-La Roche Ag |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
US8354528B2
(en)
|
2007-10-25 |
2013-01-15 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
|
EP2217601A1
(en)
|
2007-11-08 |
2010-08-18 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Imidazopyridazines for use as protein kinase inhibitors
|
|
EP2217235A4
(en)
|
2007-11-15 |
2011-01-12 |
Musc Found For Res Dev |
INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
|
|
NZ586662A
(en)
|
2007-12-19 |
2012-08-31 |
Vertex Pharma |
PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
|
|
EP2234986A2
(en)
|
2007-12-20 |
2010-10-06 |
Cellzome Limited |
Sulfamides as zap-70 inhibitors
|
|
US8168794B2
(en)
|
2008-03-03 |
2012-05-01 |
Novartis Ag |
Pim kinase inhibitors and methods of their use
|
|
AR070531A1
(es)
|
2008-03-03 |
2010-04-14 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
PT2300013T
(pt)
|
2008-05-21 |
2017-10-31 |
Ariad Pharma Inc |
Derivados de fósforo como inibidores de cinases
|
|
BRPI0909945A2
(pt)
|
2008-06-20 |
2015-07-28 |
Genentech Inc |
"composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
|
|
TWI546290B
(zh)
|
2008-06-27 |
2016-08-21 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
FR2933409B1
(fr)
|
2008-07-03 |
2010-08-27 |
Centre Nat Rech Scient |
NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
|
|
ES2660418T3
(es)
|
2008-07-16 |
2018-03-22 |
Pharmacyclics Llc |
Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
|
|
MX2011001426A
(es)
|
2008-08-05 |
2011-03-21 |
Targegen Inc |
Metodos para tratar la talasemia.
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
TWI496779B
(zh)
|
2008-08-19 |
2015-08-21 |
Array Biopharma Inc |
作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
|
|
WO2010022081A1
(en)
|
2008-08-19 |
2010-02-25 |
Array Biopharma Inc. |
Triazolopyridine compounds as pim kinase inhibitors
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
MX2011002365A
(es)
|
2008-09-02 |
2011-04-04 |
Novartis Ag |
Derivados de picolinamida como inhibidres de cinasa.
|
|
WO2010026121A1
(en)
|
2008-09-02 |
2010-03-11 |
Novartis Ag |
Bicyclic kinase inhibitors
|
|
AU2009289317A1
(en)
|
2008-09-02 |
2010-03-11 |
Novartis Ag |
Heterocyclic PIM-kinase inhibitors
|
|
US8927697B2
(en)
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
PT2350075E
(pt)
|
2008-09-22 |
2014-06-09 |
Array Biopharma Inc |
Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
|
|
KR101814408B1
(ko)
|
2008-09-26 |
2018-01-04 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
ES2539620T3
(es)
|
2008-12-19 |
2015-07-02 |
Cephalon, Inc. |
Pirrolotriazina como inhibidor de ALK y de JAK2
|
|
AU2010236389A1
(en)
|
2009-04-15 |
2011-11-24 |
Nationwide Children's Hospital, Inc. |
Curcumin analogs as dual JAK2/STAT3 inhibitors and methods of making and using the same
|
|
BRPI1011066A2
(pt)
|
2009-05-20 |
2017-03-21 |
Cylene Pharmaceuticals Inc |
"pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
|
|
US20100331315A1
(en)
|
2009-06-18 |
2010-12-30 |
Mustapha Haddach |
Rhodanines and related heterocycles as kinase inhibitors
|
|
TW201107329A
(en)
|
2009-07-30 |
2011-03-01 |
Oncotherapy Science Inc |
Fused imidazole derivative having ttk inhibitory action
|
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
EP2332917B1
(en)
|
2009-11-11 |
2012-08-01 |
Sygnis Bioscience GmbH & Co. KG |
Compounds for PIM kinase inhibition and for treating malignancy
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
EP2515665B1
(en)
|
2009-12-22 |
2013-08-14 |
Unilever NV |
A process for preparing a tea product
|
|
PL2516425T3
(pl)
|
2009-12-23 |
2016-03-31 |
Jasco Pharmaceuticals Llc |
Inhibitory kinaz aminopirydynowych
|
|
UY33213A
(es)
|
2010-02-18 |
2011-09-30 |
Almirall Sa |
Derivados de pirazol como inhibidores de jak
|
|
CN102892786B
(zh)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
|
CN107898791A
(zh)
|
2010-06-03 |
2018-04-13 |
药品循环有限责任公司 |
布鲁顿酪氨酸激酶(btk)抑制剂的应用
|
|
WO2011155607A1
(ja)
|
2010-06-11 |
2011-12-15 |
協和発酵キリン株式会社 |
抗ｔｉｍ－３抗体
|
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
JP2013530199A
(ja)
|
2010-07-06 |
2013-07-25 |
ノバルティス アーゲー |
キナーゼ阻害剤として有用な環状エーテル化合物
|
|
TWI541243B
(zh)
|
2010-09-10 |
2016-07-11 |
拜耳知識產權公司 |
經取代咪唑并嗒
|
|
EP2614065B1
(en)
|
2010-12-17 |
2017-04-19 |
Nerviano Medical Sciences S.r.l. |
Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
|
|
PL2678329T3
(pl)
|
2011-02-25 |
2016-06-30 |
Array Biopharma Inc |
Związki triazolopirydyny jako inhibitory kinaz pim
|
|
WO2012120415A1
(en)
|
2011-03-04 |
2012-09-13 |
Novartis Ag |
Tetrasubstituted cyclohexyl compounds as kinase inhibitors
|
|
EP2688886A1
(en)
|
2011-03-22 |
2014-01-29 |
Amgen Inc. |
Azole compounds as pim inhibitors
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
ES2595407T3
(es)
|
2011-06-14 |
2016-12-29 |
Novartis Ag |
Combinación de panobinostat y ruxolitinib en el tratamiento de cáncer, tal como una neoplasia mieloproliferativa
|
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
US9138436B2
(en)
|
2011-07-13 |
2015-09-22 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
JP6240600B2
(ja)
|
2011-07-24 |
2017-11-29 |
キュアテク リミテッド |
ヒト化免疫モノクローナル抗体の変異体
|
|
CN102924445B
(zh)
|
2011-08-11 |
2015-07-08 |
上海吉铠医药科技有限公司 |
Pim激酶抑制剂及其制备方法与在制药中的应用
|
|
WO2013059738A2
(en)
|
2011-10-19 |
2013-04-25 |
Pharmacyclics, Inc. |
Use of inhibitors of bruton's tyrosine kinase (btk)
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
|
RU2014140739A
(ru)
|
2012-03-09 |
2016-04-27 |
Лексикон Фармасьютикалз, Инк. |
Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
|
|
WO2013173518A1
(en)
|
2012-05-16 |
2013-11-21 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
US9173883B2
(en)
|
2012-05-21 |
2015-11-03 |
Novartis Ag |
Ring-substituted N-pyridinyl amides as kinase inhibitors
|
|
HK1204557A1
(en)
|
2012-05-31 |
2015-11-27 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-l1
|
|
JO3754B1
(ar)
|
2012-06-04 |
2021-01-31 |
Pharmacyclics Llc |
أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CN104704129A
(zh)
|
2012-07-24 |
2015-06-10 |
药品循环公司 |
与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
|
|
US8703981B2
(en)
|
2012-08-03 |
2014-04-22 |
Xerox Corporation |
Lignosulfonate compounds for solid ink applications
|
|
JP6403166B2
(ja)
|
2012-08-03 |
2018-10-10 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法
|
|
BR112015002709B1
(pt)
|
2012-08-06 |
2022-09-20 |
Acea Biosciences Inc |
Compostos, composição farmacêutica, uso dos mesmos e uso de uma combinação de composto ou composição farmacêutica e um segundo agente profilático ou agente terapêutico
|
|
KR101446742B1
(ko)
|
2012-08-10 |
2014-10-01 |
한국화학연구원 |
Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
|
CN102880459A
(zh)
|
2012-08-14 |
2013-01-16 |
张涛 |
基于VisualLisp编程语言下的编译实现方法及系统
|
|
US9315514B2
(en)
|
2012-08-27 |
2016-04-19 |
Rhodes Technologies |
1,3-dioxanomorphides and 1,3-dioxanocodides
|
|
WO2014033631A1
(en)
|
2012-08-31 |
2014-03-06 |
Novartis Ag |
N-(3-pyridyl) biarylamides as kinase inhibitors
|
|
CN104812756A
(zh)
|
2012-09-26 |
2015-07-29 |
曼凯德公司 |
多激酶通路抑制剂
|
|
CA2886433C
(en)
|
2012-10-04 |
2022-01-04 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
|
EA201590855A1
(ru)
|
2012-11-15 |
2015-11-30 |
Фармасайкликс, Инк. |
Соединения пирролопиримидина как ингибиторы киназ
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
RS60244B1
(sr)
|
2013-01-15 |
2020-06-30 |
Incyte Holdings Corp |
Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
|
|
AU2014214846A1
(en)
|
2013-02-08 |
2015-07-23 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
|
US10322125B2
(en)
|
2013-02-22 |
2019-06-18 |
Emory University |
TGF-beta enhancing compositions for cartilage repair and methods related thereto
|
|
WO2014130693A1
(en)
|
2013-02-25 |
2014-08-28 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
JP2016512549A
(ja)
|
2013-03-14 |
2016-04-28 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
|
|
EA037554B1
(ru)
|
2013-03-15 |
2021-04-13 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Анти-lag-3 связывающие белки
|
|
HK1215374A1
(zh)
|
2013-04-08 |
2016-08-26 |
Pharmacyclics Llc |
依鲁替尼联合疗法
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
|
KR102094011B1
(ko)
|
2013-06-13 |
2020-03-26 |
삼성전자주식회사 |
전자 장치에서 노이즈를 제거하기 위한 장치 및 방법
|
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
JP6458018B2
(ja)
|
2013-07-02 |
2019-01-23 |
ファーマサイクリックス エルエルシー |
キナーゼ阻害剤としてのプリノン化合物
|
|
JP2016527305A
(ja)
|
2013-08-08 |
2016-09-08 |
ノバルティス アーゲー |
Ｐｉｍキナーゼ阻害剤の組合せ
|
|
CN105658653A
(zh)
|
2013-08-23 |
2016-06-08 |
因赛特公司 |
可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
CA2925124A1
(en)
|
2013-09-30 |
2015-04-02 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
WO2015061668A1
(en)
|
2013-10-25 |
2015-04-30 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
|
WO2015081158A1
(en)
|
2013-11-26 |
2015-06-04 |
Bristol-Myers Squibb Company |
Method of treating hiv by disrupting pd-1/pd-l1 signaling
|
|
AU2014354821A1
(en)
|
2013-11-27 |
2016-05-26 |
Novartis Ag |
Combination therapy comprising an inhibitor of JAK, CDK and PIM
|
|
MY184154A
(en)
|
2013-12-12 |
2021-03-23 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
SI3094351T1
(sl)
|
2014-01-15 |
2022-05-31 |
Kadmon Corporation, Llc |
Imunomodulatorna sredstva
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
EP3099716A1
(en)
|
2014-01-28 |
2016-12-07 |
Bristol-Myers Squibb Company |
Anti-lag-3 antibodies to treat hematological malignancies
|
|
EP3099717B1
(en)
|
2014-01-31 |
2019-03-27 |
Novartis AG |
Antibody molecules to tim-3 and uses thereof
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
PH12020552277A1
(en)
|
2014-04-08 |
2023-07-17 |
Incyte Holdings Corp |
Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
|
|
US20150306112A1
(en)
|
2014-04-25 |
2015-10-29 |
National Cheng Kung University |
Zhankuic acid A, a JAK2/3 tyrosine kinase inhibitor, and a potential therapeutic agent for hepatitis
|
|
EP3149042B1
(en)
|
2014-05-29 |
2019-08-28 |
Spring Bioscience Corporation |
Pd-l1 antibodies and uses thereof
|
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對ｐｄ－ｌ１之抗體分子及其用途
|
|
PT3215532T
(pt)
|
2014-11-06 |
2019-12-18 |
Hoffmann La Roche |
Anticorpos anti-tim3 e métodos de utilização
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
CA2978892A1
(en)
|
2015-03-06 |
2016-09-15 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind tim3
|
|
EA201792184A1
(ru)
|
2015-04-01 |
2018-04-30 |
Анаптисбайо, Инк. |
Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
|
|
WO2016161248A1
(en)
|
2015-04-02 |
2016-10-06 |
Tolero Pharmaceuticals, Inc. |
Targeting pim kinases in combination with btk inhibition
|
|
PL3978500T3
(pl)
*
|
2015-12-16 |
2024-03-11 |
Genentech, Inc. |
Sposób wytwarzania tricyklicznych związków inhibitorów pi3k
|
|
CN105919955A
(zh)
|
2016-06-13 |
2016-09-07 |
佛山市腾瑞医药科技有限公司 |
一种鲁索利替尼制剂及其应用
|
|
CN117838695A
(zh)
|
2018-04-13 |
2024-04-09 |
住友制药肿瘤公司 |
用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
WO2021080955A1
(en)
|
2019-10-21 |
2021-04-29 |
Celgene Corporation |
Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
|